BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 25
• 26
• 27
• 28

• Business

  Halozyme Reports Fourth Quarter And Full-Year 2017 Results

  Halozyme Therapeutics, Inc. today reported financial results and recent highlights for the fourth quarter and full-year ended December 31, 2017.

  February 20, 2018

   · 

  15 min read
• Business

  TherapeuticsMD Announces Fourth Quarter and Full Year 2017 Financial Results

  TherapeuticsMD, Inc., an innovative women’s healthcare company, today announced its fourth quarter and full-year financial results for 2017.

  February 20, 2018

   · 

  11 min read
• Biotech Bay

  Aimmune Therapeutics Announces Proposed Public Offering of Common Stock

  Aimmune Therapeutics announced that it has commenced an underwritten public offering of up to $150,000,000 of shares of its common stock.

  February 20, 2018

   · 

  3 min read
• Drug Development

  Achieve Announces Preliminary Data from Cytisine Phase I/II Clinical Study

  Achieve Life Sciences, Inc. announced preliminary data from their Phase I/II multi-dose, pharmacokinetic and pharmacodynamics (PK/PD) clinical study of cytisine.

  February 20, 2018

   · 

  5 min read
• Policy

  Acorda Announces FDA Acceptance of New Drug Application for INBRIJA™ (levodopa inhalation powder)

  INBRIJA is an investigational inhaled levodopa treatment for symptoms of OFF periods in people with Parkinson’s disease taking a carbidopa/levodopa regimen.

  February 20, 2018

   · 

  5 min read
• Drug Development

  GenSight Biologics Announces Publication of Positive Data from Phase I/II Trial and Long-Term Follow-up of GS010 in Ophthalmology, the Journal of the American Academy of Ophthalmology

  The study demonstrated that GS010 (rAAV2/2-ND4) is safe and well tolerated 2 years after a single unilateral intravitreal administration.

  February 20, 2018

   · 

  7 min read
• Drug Development

  Kancera AB Reports Positive Results from a Phase I Study

  Kancera AB is seeing encouraging results from its Phase 1 study with its Lead Immunoregulating Drug Candidate KAND567.

  February 20, 2018

   · 

  2 min read
• Business

  CSI Laboratories Announces Construction of New Cancer Diagnostics Laboratory in Florida

  CSI Laboratories, a national cancer diagnostics laboratory based in Atlanta, Georgia, is expanding its operations to Jupiter, Florida.

  February 20, 2018

   · 

  2 min read
• Business

  Cannabics Pharmaceuticals Hires Chief Data Officer to Address Industry Compliance and Utilization/Analytics Application

  Cannabics Pharmaceuticals announced the appointment of Yasha Borstein as the company’s Chief Data Officer.

  February 20, 2018

   · 

  4 min read
• Business

  Solaris Nutraceuticals and Southern Cross University Team Up for Pain Relief Joint Venture

  Announcement of a joint venture agreement between Southern Cross University and Solaris Nutraceuticals to commit to the development of hemp and medicinal cannabis products in the NSW Northern Rivers region that will enhance animal and human health.

  February 20, 2018

   · 

  6 min read